Ampersand Capital Partners has acquired Tucson, Arizona-based Protein Technologies, a maker of peptide synthesizers and reagents. No financial terms were disclosed. In addition to the transaction, Square 1 Bank provided working capital financing to Protein Technologies.
WELLESLEY, Mass. & TUCSON, Ariz.–(BUSINESS WIRE)–Ampersand Capital Partners, a private equity firm with a focus on growth equity investments in the healthcare sector, today announced the purchase of Protein Technologies, Inc., a leader in the field of peptide synthesis instrumentation. Terms of the transaction were not disclosed.
The acquisition solidifies Protein Technologies’ financial position to expand the business and meet the needs of an increasingly global customer base. Nate Cosper, Ph.D., will continue to serve as President and CEO of the Company.
“Protein Technologies has a longstanding history of providing high quality synthesizers, and our employees are dedicated to delivering exceptional support to customers in the peptide synthesis community,” Dr. Cosper said. “Ampersand’s acquisition further strengthens our balance sheet, enabling our company to accelerate development of new products and enhance the level of service that we provide to our customers.”
“Protein Technologies is the recognized leader in a segment of the life sciences instrument market that is experiencing strong demand based on worldwide research interest in novel, peptide-based therapies,” said David Parker, General Partner at Ampersand. “Ampersand is partnering with the Protein Technologies team to further advance the Company’s innovative instrument and reagent solutions for the global peptide community.”
Square 1 Bank has provided working capital financing concurrent with Ampersand’s investment to further support the future growth of Protein Technologies.
About Protein Technologies, Inc.
Founded in 1985, Protein Technologies, Inc. designs, manufactures and supplies peptide synthesizers and reagents to academic and commercial researchers at leading universities, biotechnology and pharmaceutical companies. Based in Tucson, Arizona, Protein Technologies is committed to delivering quality products and uncompromised customer service built on reliability and trust. As market demand for peptide therapeutics increases, Protein Technologies continues to evolve to consistently deliver innovative technologies that improve the efficiency of drug discovery. To learn more about Protein Technologies, please visit www.ptipep.com.
About Ampersand Capital Partners
Ampersand is a middle market private equity firm with a focus on growth equity investments in the healthcare sector. Over the past two decades, Ampersand has managed $1 billion in private equity partnerships. Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Additional information about Ampersand is available at www.ampersandcapital.com.